GCC Pompe Disease Launch Readiness

Alglucosidase alfa (Lumizyme/Myozyme) is SFDA-registered and NPHC-covered as the entrenched GCC standard of care, with Sanofi running an established home-infusion pilot at KFSH&RC since 2022-2024 covering roughly 30 patients in Riyadh. Avalglucosidase alfa (Nexviazyme), Sanofi's own next-generation ERT, has a pending or recent SFDA registration with NPHC switch criteria still forming — meaning Sanofi is managing its own internal cannibalisation, and any external new entrant faces a company that already controls both the incumbent molecule and the infrastructure relationship.

GCC LOPD prevalence is consanguinity-elevated at an estimated 1/25,000-35,000 (versus a global 1/57,000), yielding 400-600 total GCC Pompe patients, of whom 200-300 are on ERT. The most clinically urgent and commercially actionable segment is narrower: 40-60 patients with FVC decline despite alglucosidase, already on home non-invasive ventilation, who represent inadequate responders. Reaching them requires clearing the NPHC step-edit — 12 months of documented alglucosidase failure, or an ADA-positive pathway that can waive the wait if a high-titre ADA response is confirmed via KFSH&RC's ELISA assay. Adult LOPD diagnosis itself is delayed 8-12 years in GCC, longer than the US 7-10, due to lower GAA-enzyme-testing awareness among community neurologists managing proximal-myopathy differentials.

Pre-launch action: build an independent ADA testing programme to identify inadequate responders ahead of the 12-month step-edit wait; establish an own home-infusion nursing partnership (Bayada, Almana Medical Homecare, or other GCC home healthcare networks) as a launch prerequisite, not an optional extra; prepare GCC-relevant ADA+ subgroup clinical data for the NPHC HTA dossier; and lead the commercial argument with ventilator-avoidance cost savings, which NPHC directly tracks.

This assessment synthesises three research angles into one launch-readiness view: competitive positioning (Sanofi's dual-ERT and home-infusion entrenchment), target-population epidemiology (ADA+ inadequate-responder sizing and adult diagnostic-delay analysis), and anticipated GCC payer posture (NPHC step-edit criteria and pricing benchmarks). Anticipated payer posture is derived from the NPHC step-edit precedent applied to avalglucosidase and is clearly separated from confirmed policy for any new external entrant.

Sources: GCC genetics and rare disease society Pompe case registry, KFSH&RC Pompe programme outcomes and home infusion programme report, Saudi consanguinity Pompe prevalence data, NPHC Pompe rare metabolic disease coverage framework, and Sanofi GCC patient services data.